AU599603B2 - Process for preparation of antigens using radio active stilbene derivatives labelled with iodine and the antigens obtained - Google Patents
Process for preparation of antigens using radio active stilbene derivatives labelled with iodine and the antigens obtained Download PDFInfo
- Publication number
- AU599603B2 AU599603B2 AU63536/86A AU6353686A AU599603B2 AU 599603 B2 AU599603 B2 AU 599603B2 AU 63536/86 A AU63536/86 A AU 63536/86A AU 6353686 A AU6353686 A AU 6353686A AU 599603 B2 AU599603 B2 AU 599603B2
- Authority
- AU
- Australia
- Prior art keywords
- antigens
- serum albumin
- preparation
- formula
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000427 antigen Substances 0.000 title claims description 27
- 102000036639 antigens Human genes 0.000 title claims description 27
- 108091007433 antigens Proteins 0.000 title claims description 27
- 238000002360 preparation method Methods 0.000 title claims description 13
- 238000000034 method Methods 0.000 title claims description 10
- 229910052740 iodine Inorganic materials 0.000 title description 6
- 239000011630 iodine Substances 0.000 title description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 title description 5
- 230000002285 radioactive effect Effects 0.000 title description 4
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 18
- 229940098773 bovine serum albumin Drugs 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 14
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 150000008064 anhydrides Chemical class 0.000 claims description 8
- 230000003213 activating effect Effects 0.000 claims description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical group CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- PHKJVUUMSPASRG-UHFFFAOYSA-N 4-[4-chloro-5-(2,6-dimethyl-8-pentan-3-ylimidazo[1,2-b]pyridazin-3-yl)-1,3-thiazol-2-yl]morpholine Chemical compound CC=1N=C2C(C(CC)CC)=CC(C)=NN2C=1C(=C(N=1)Cl)SC=1N1CCOCC1 PHKJVUUMSPASRG-UHFFFAOYSA-N 0.000 claims 1
- 102100021752 Corticoliberin Human genes 0.000 claims 1
- 101000895481 Homo sapiens Corticoliberin Proteins 0.000 claims 1
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 19
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 19
- 229950001996 hexestrol Drugs 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- NFDFQCUYFHCNBW-SCGPFSFSSA-N dienestrol Chemical compound C=1C=C(O)C=CC=1\C(=C/C)\C(=C\C)\C1=CC=C(O)C=C1 NFDFQCUYFHCNBW-SCGPFSFSSA-N 0.000 description 16
- 229960003839 dienestrol Drugs 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 229960001340 histamine Drugs 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 6
- 229960000452 diethylstilbestrol Drugs 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 235000021286 stilbenes Nutrition 0.000 description 4
- AVMSWPWPYJVYKY-UHFFFAOYSA-N 2-Methylpropyl formate Chemical compound CC(C)COC=O AVMSWPWPYJVYKY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000001629 stilbenes Chemical class 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N trans-stilbene Chemical class C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 241000928106 Alain Species 0.000 description 1
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- XIMFCGSNSKXPBO-UHFFFAOYSA-N ethyl 2-bromobutanoate Chemical compound CCOC(=O)C(Br)CC XIMFCGSNSKXPBO-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000004296 sodium metabisulphite Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
i! r 1 r 599603 Australia Form PATENTS ACT 1952 COMPLETE SPECIFICATION
(ORIGINAL)
FOR OFFICE USE Short Title: Int. CI: 3.3 7 R.
Application Number: Lodged: p Complete Sr:ecifiction-Lodged: i Accepted: S Lapsed: S Published: Friority: Related Art:
I:
TO BE
ROUSSEL-UCLAF
COMPLETED BY APPLICANT rNme of Applicant: i A I S ddress of Applicant: I 4 Actual Inventor: Address for Service: 35 Boulevard des Invalides, 75007, Paris, France ALAIN JOUQUEY and GAETAN TOPUYER CALLINAN AND ASSOCIATES, Patent Attorneys, of 48-50 Bridge Road, Richmond, State of Victoria, Australia.
Complete Specification for the invention entitled: "PROCESS FOR PREPARATION OF ANTIGENS USING RADIO ACTIVE STILBENE DERIVATIVES LABELLED WITH IODINE AND THE ANTIGENS OBTAINED." The following statement is a full description of this invention, including the best method of performing it known to me:-* SNote: The description is to be typed in double spacing, pica type face, in an area not exceeding 250 mm in depth and 160 mm in width, on touph white paper of good quality and it is to be inserted inside this form.
I
L 1 The subject of the present invention is a process for preparation of antigens using radioactive stilbene 125 131 derivatives labelled with iodine or and the antigens obtained.
The radioactive stilbene derivatives labelled with 125 131 iodine 125 or iodine 13, of general formula I: cnH o C) 0 ftN 00 0 oa on o Sin which A and B each represent a hydrogen atom or o 00 together represent a double bond and R represents the 0 residue of an amino acid RNH 2 or the residue of a deriv- 9 *4 0 0 0 oIo0 ative of the latter, this residue possessing an iodineo o 125 131 accepting group and being labelled with iodine or 668,' and their preparation, are described in Australian Patent 0 Application No. 85488/82.
Throughout this specification the numbers designating formulae have the same function as those used in Australian Patent Application No. 85488/82.
The compounds of general formula VI -2- 0]
HO
0 -(CH.%coo,
~CH.
mKe 0 00 oo 0 o on 0 o 0 0 0 O 00Q 00 0a O .q 0 00 00 o o6 O 00 oa 9 0 0 0000 6 in which A and B each represent a hydrogen atom or together represent a double bond and R 3 represents a hydrogen atom, an alkyl radical having at most six carbon atoms or a group activating the carbonyl function, and more particularly those corresponding to formula IV
CRH
oCHH in which A and B are as hereinbefore defined, are useful starting compounds for the preparation of antigens, also necessary for radioimmunological dosing of diethylstilbestrol, of dienestrol and of hexestrol.
-3- S0 0 0o 0 00 0 04 00 0 0 0 00 0 04 010 4 The group activating the carbonyl function can be especially a radical of formula -CO-O-Alk, in which Alk represents an alkyl radical having at most six carbon atoms.
The subject of the present invention is a process for the preparation of antigens, wherein a compound of formula VI, as hereinbefore described, is conjugated with bovine serum albumin (BSA) or with human serum albumin (HSA) and the antigen sought is obtained.
L-i]er preferred conditions of use, the use of compounds of general formula IV is characterised by the following points: a compound of general formula IV: ctii LO OH CR H in which and in the following A and B have the meanings already mentioned, with a view to activating the carbonyl function, is reacted with an alkyl haloformate, in the presence of a tertiary base, in anhydrous medium and under inert atmosphere, and the mixed anhydride of -4formula V: RHO-(c \'o ccH 0H in which R 2 is a group activating the carbonyl function, of formula -CO-O-Alk, Alk being an alkyl radical having at most six carbon atoms, is obtained, o° which is conjugated with bovine serum albumin (BSA) or human serum albumin (HSA) and the antigen sought is 0n ~0 obtained.
0 00 0 0 The use of the compounds of general formula IV is further characterised by the following modi operandi: 0Q, the alkyl haloformate which is reacted with the product of general formula IV is isobutyl chloroformate and work 0000 060t is carried out in the presence of tri-n-butylamine, in anhydrous dioxan and under inert atmosphere at about 3 4 0 C and the mixed anhydride of general formula V is reacted with bovine or human serum albumin, the latter having been previously dissolved in a mixture of water and dioxan under inert atmosphere.
IL--
~1 The use described enables there to be obtained respectively: starting with the dienestrol of formula:
CH
140! C 0
CO
3 00 0 0 lit, the antigens of formulae: C H
CH
OHfO in which n 20 to 40; and -6o (CHa) CO 71, (7lZZI 00 00 00 0 0 0 0 0 0 000 0 000 00 0 0 00 0 00 00.0 08004 00-64 a000 0 00 00 0 o 04 CHi in which n =20 to and starting with the hexestrol of formula: 0001-1 CO/ the antigens of formulae: 7- Co0 0 0 0 0**4 0 4 in which n 20 to 40; and
CH,.
Ho Ia HOCHc (HER6f) in which n 20 to The subject of the invention is also, as new industrial products, the antigens obtained during the use described above, that is to say the aforementioned products of general formulae VII, VIII, IX an d X.
The subject of the invention is also the use of the antigens above in the preparation of antibodies.
The compounds of general formula I, which form the subject of the invention which is the subject of Australian Patent Application No. 85488/82, and espec- 125 ially dienestrol 4-0-monocarboxypropyl I) histamine 125 and hexestrol 4-0-monocarboxypropyl I) histamine are used in the radioimmunological dosing of dienestrol, of hexestrol as well as of diethylstilbestrol.
They permit the dosina of these stilbenes in biological liquids and tissues and in human and animal Sfeeding.
The radioimmunological dosing is carried out according to the method described by S.A. Bergson and R.S. Yalow, Hormone 4, page 557 (1964) and G.E. Abraham "Journal of Chemical endocrinonal metab" 29, page 866, (1969).
The aforementioned antigens of formulae VII, VIII, IX and X which form a subject of the present invention, are used for the development of antibodies. Injected into an animal in the presence of an adjuvant, they enable, in effect, serums to be obtained from the animal, containing antibodies against hexestrol, dienestrol as well as against diethylstilbestrol.
An amide formed with histamine and diethylstilbestrol 4-0-(carboxypropyl) substituted on the -9larrrp-- -rr~ l-lil-L-.i-~-l 125 histamine residue with iodine is described by H.J.
Johnson, S.F. Cernosek and R.M. Gutierrez-Cernosek in "Journal of Labelled Compounds and Radiopharmaceuticals", Vol. XVI no. 3 p. 501-506. In this document, this compound is badly defined. Moreover, the radioimmunological dosing of diethylstilbestrol is only permitted and that, with a slight sensibility. In short, it does not permit the dosing of other stilbenes such as dienestrol and hexestrol. On the other hand, the compounds of formula I of the present invention permit 0 0° not only the dosing with a great precision of dienestrol and hexestrol but also of diethylstilbestrol. In support 0 00 OP 6° of that, the possible analysis of traces of these 0 0 P stilbenes in carcasses tissues, corporeal liquids, excretions of bovines can be cited as examples.
The following examples illustrate the invention 0 without, however, limiting it.
L7 Example I: Dienestrol 4-0-monocarboxypropyl coupled to 125 I) histamine.
Stage A: Dienestrol A mixture of 20 g of dienestrol, 7 g of ethyl bromobutyrate and 4.6 g of dry potassium carbonate in 300 ml of acetone is prepared, this mixture is taken to reflux for about seventeen hours, allowed to cool then at ambient temperature poured into water and extracted with o S o ethyl acetate, the combined organic phases are washed I oL0 with water, dried and treated with active charcoal, the solvent is evaporated and the residue is dried under So° reduced pressure. 24.4 g of a semi-crystalline residue !H are recovered which is purified by chromatography on i silica under pressure with elution with the mixture 25- methylene chloride/methanol (95/5) and 6.36 g of product 0 0 0 I sought are obtained, M.Pt. about 860C.
no IR Spectrum (chloroform) r-1 0 .2 OH about 3590 cm i o C O about 1728 cm 1 iq -l Aromatic about 1610 cm 1590 cm -i 1573 cm -1 1510 cm Stage B: Dienestrol 6.16 g of product obtained in the previous stage and 31 ml of 2N sodium hydroxide are introduced into 155 -11ml of methanol and the resulting solution is taken to V reflux for one hour. After cooling to ambient temperature, the pH is brought to 5-6 by the addition of 7 ml of acetic acid, the reaction mixture is poured into water, the whole is extracted with ethyl acetate, the organic phases are combined, washed with water, dried and treated with active charcoal, the solvent is evaporated, the residue is concentrated to dryness under reduced pressure and 5.48 g of crude product are 0°l obtained. This product is purified by conversion to 0 0 Sa* o the sodium salt and returning to the free acid and 5.16 oo o00 S* g of product sought are obtained, M.Pt. 158 C.
0 00 Analysis C22H2404 C% H% 0 0.
°1 3 "Calculated 74.98 6.86 0 0 Found 74.7 o" Stage C: Mixed anhydride of isobutyl formate and o dienestrol o .o 2.5 mg of product prepared in the previous stage, 50 pl of dioxan, 10 pl of a dioxan/tri-n-butylamine mixture and 10 pl of a dioxan/isobutyl chloroformate I mixture (10:1) are mixed successively. The solution is agitated for 30 minutes under inert atmosphere, then 3.4 ml of dioxan are added. A solution of the product sought is isolated, which is used as it is for the following stage of the synthesis.
-12- 17 Stage D: Dienestrol 4-0-monocarboxypropyl coupled to 125 125I) histamine Iodination of the histamine: -4 pi of a 104 M solution of histamine in a 0.5 M sodium phosphate buffer solution of pH 8 are prepared 125 then 1 mCi of sodium iodide 125I (specific activity 2,000 Ci/m.mol) in 5 4l of distilled water and 50 pg of chloramine T in 10 pi of distilled water are added o" successively. The reaction mixture is agitated for :if seconds, a solution of 300 pg of sodium metabisulphite dissolved in 10 pi of distilled water is added and an aqueous solution of the product sought is obtained, Rf 0.1 (chromatography on silica, solvent system methanol/triethylamine, 98:2).
T'i* Condensation: To this solution are added 50 pl of the mixed tanhydride solution obtained in the previous stage and 1 the whole is agitated and left in the dark for 2 hours at a temperature close to 4 0 C. The reaction mixture is then diluted with 0.3 ml of a 10 1 M aqueous solution of sodium bicarbonate and extracted with 1.5 ml of methylene chloride, the organic phase is evaporated under inert atmosphere, the residue is taken up with 100 pi of methylene chloride and chromatographed on silica, elution being carried out with the chloroform/methanol mixture (97:3) and the fractions containing the product are -13combined. The product obtained shows a total activity of 100 pCi.
Example II: Hexestrol 4-0-monocarboxypropyl coupled to 125 125I) histamine.
By proceeding as described in Example I and starting with hexestrol, there are obtained: 6.7 g of hexestrol 4-0-monoethoxycarbonylpropyl, M.Pt.
about 110 0
C.
IR Spectrum (chloroform) o0 o -1 OH about 3590 cm S 0-1 v C 0 about 1725 cm eo a o 000 -1 o o Aromatic 1610 cm 0 0 -1 .00 1594 cm -i 1580 cm 1 °i^ 1508 cm 0* So* 4.5 g of hexestrol 4-0-monocarboxypropyl, M.Pt. about 183 C.
Analysis
C
2 2 H2804 S, C% H% Calculated 74.13 7.92 Found 74.4 8.1 the mixed anhydride of hexestrol with isobutyl formate and hexestrol 4-0-monocarboxypropyl coupled to (125 I) histamine showing a total activity of 100 pCi.
-14- Example III: Preparation of antigen by conjugating dienestrol 4-0-monocarboxypropyl and bovine serum albumin
(BSA).
Stage A: Mixed anhydride of dienestrol propyl with isobutyl formate 325 mg of dienestrol 4-0-monocarboxypropyl are dissolved in 10 ml of dioxan, then 0.46 ml of tri-nbutylamine is added and the mixture is agitated under a inert atmosphere. The temperature is lowered to 12 0
C
1" and 0.126 ml of isobutyl chloroformate is added and the O 4 o. agitation is kept up for 30 minutes at 12°C. The solut- 04 00 o ion of the product sought is obtained which is used as 0 0 it is for the following stage.
Stage B: Dissolution of the BSA A mixture of 44 ml of iced water and 4 ml of dioxan is prepared, then 1.54 g of bovine serum albumin are 0004 added, with agitation and at a temperature close to 0 C.
The resulting solution is then decanted into a dialysis 04 *apparatus and left for 72 hours to dialyse at a temperature of between 10 and 5 0 C, with a counterflow of 30 1 of water.
The dialysate obtained (pH 7.9) is then extracted with iced chloroform and the organic phases are separated and washed with water. The aqueous phases are combined, frozen, then lyophilised for 20 hours under vacuum of 0.01 mm Hg and 1.4 g of product are obtained.
Stage C: Conjugation: The residue obtained above is dissolved at 0 C in ml of iced dioxan, then 1.35 ml of N NaOH are added and immediately afterwards the mixed anhydride prepared in Stage A. The pH is adjusted to 8.9 by the addition of N/10 hydrochloric acid and the reaction mixture is left for 4 hours with agitation, at a temperature close to 0 0 C. It is then subjected to dialysis for 18 hours, at a temperature included between 1 C and 5 C, with a counter-current of water. After the passage of 30 litres o 0o 0. of water, the dialysate is decanted, acidified to pH 4.1 0o 0o S with N, then N/10 hydrochloric acid, frozen for one night °at about -18 C, then thawed slowly without exceeding A precipitate is formed and the supernatant solution is eliminated by filtration. The precipitate is taken up with 100 ml of a 1% solution of sodium bicarbonate and the solution is subjected to dialysis for 72 hours under the aforementioned conditions. The dialysate is then sa, extracted with iced chloroform and the organic phase is washed with water. The combined aqueous phases are frozen, then lyophilised for 20 hours under a vacuum of 0.01 mm Hg to give 1.4 g of antigen sought.
This product contains 37 to 38 bonded dienestrol groups per mole.
-16- Example IV: Preparation of antigen by conjugating hexestrol 4-0-monocarboxypropyl and bovine serum albumin
(BSA).
By proceeding as described in Example III, starting with 356 mg of hexestrol 4-0-monocarboxypropyl and 1.54 g of bovine serum albumin (BSA), 1.3 g of antigen sought are obtained. This product contains 31 to 32 groups of hexestrol per mole.
Example V: Preparation of antigen by conjugating 0* hexestrol 4-0-monocarboxypropyl and human serum albumin o 0a c (HSA).
o o o By proceeding as described in Example III, starto a ing with 356 mg of hexestrol 4-0-monocarboxypropyl and 1.54 g of human serum albumin (HSA), 1.17 g of the antigen "T3 sought are obtained. This product contains 21 bonded 0 00 hexestrol groups per mole.
art 46os 0-17 t -17-
Claims (4)
1. A process for preparation of antigens, wherein a compound of formula VI: CHI zH3 0o e 0 00 S°°in which A and B each represent a hydrogen atom or 0 9 4 together represent a double bond and R 3 represents a hydrogen atom, 00 3 °I is conjugated with bovine serum albumin (BSA) or with human serum albumin (HSA) and the antigen sought is 0 40 obtained. S2. A process according to claim 1, wherein: 0 o. a compound of general formula IV: CRH1 I a t13 I claim 1, with a view to activating the carbonyl function, is reacted with an alkyl haloformate, in the presence of -18- a tertiary base, in anhydrous medium and under inert atmosphere and the mixed anhydride of formula V CH3 cHH -00 c 0 o in which R 2 represents a radical of formula -CO-O-Alk, oAo 0 Alk being an alkyl radical having at most 6 carbon atoms, is obtained, which is conjugated with bovine serum albumin (BSA) or human serum albumin (HSA) and the 00 antigen sought is obtained.
3. Process according to claim 2, wherein: 0 the alkyl haloformate which is reacted with a compound of general formula IV is isobutyl chloroformate and in oa' which the reaction is carried out in the presence of i tri-n-butylamine, in anhydrous dioxan and under inert atmosphere at about +4 0 C; and the mixed anhydride of general formula V is reacted with bovine or human serum albumin, the latter previously having been dissolved in a mixture of water and dioxan under inert atmosphere.
4. The antigens of formulae: -19- L7 NO 1 C 2in which n equals 20 to CH 0~ 00 >1 4-C4J- O8P in which n equals 20 to 40; n Ic sr P) 6 in which n equals 20 to Use of the antigens according to claim 4 in the preparation of antibodies.
6. A process for the preparation of an antigen as claimed in claim 4 substantially as hereinbefore described with reference to any one of Examples III os to V. D A T E D this 6th day of October, 1986. 9r ROUSSEL-UCLAF By its Patent Attorneys: CALLINAN AND ASSOCIATES I -2.1-
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8112934 | 1981-07-01 | ||
| FR8112934A FR2508905B1 (en) | 1981-07-01 | 1981-07-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU85488/82A Division AU558848B2 (en) | 1981-07-01 | 1982-06-30 | Radioactive stilbene derivatives labelled with iodine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6353686A AU6353686A (en) | 1987-01-08 |
| AU599603B2 true AU599603B2 (en) | 1990-07-26 |
Family
ID=9260076
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU85488/82A Ceased AU558848B2 (en) | 1981-07-01 | 1982-06-30 | Radioactive stilbene derivatives labelled with iodine |
| AU63535/86A Ceased AU579751B2 (en) | 1981-07-01 | 1986-10-06 | Intermediates for the preparation of radio-active stilbene derivatives labelled with iodine and process for preparing them |
| AU63536/86A Ceased AU599603B2 (en) | 1981-07-01 | 1986-10-06 | Process for preparation of antigens using radio active stilbene derivatives labelled with iodine and the antigens obtained |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU85488/82A Ceased AU558848B2 (en) | 1981-07-01 | 1982-06-30 | Radioactive stilbene derivatives labelled with iodine |
| AU63535/86A Ceased AU579751B2 (en) | 1981-07-01 | 1986-10-06 | Intermediates for the preparation of radio-active stilbene derivatives labelled with iodine and process for preparing them |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4529713A (en) |
| EP (2) | EP0069018B1 (en) |
| AR (1) | AR244205A1 (en) |
| AT (1) | ATE18214T1 (en) |
| AU (3) | AU558848B2 (en) |
| CA (1) | CA1207775A (en) |
| DE (1) | DE3269359D1 (en) |
| DK (1) | DK165368C (en) |
| FR (1) | FR2508905B1 (en) |
| IE (1) | IE54489B1 (en) |
| NZ (1) | NZ201130A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572177D1 (en) * | 1984-10-19 | 1989-09-14 | Nihon Mediphysics Co Ltd | IMUNOASSAY FOR ESTRIOL-3 SULFATE |
| DE3674575D1 (en) * | 1985-12-27 | 1990-10-31 | Daicel Chem | USE OF OPTICALLY ACTIVE CARBOALKYLATED AMINO ALCOHOLS FOR THE SEPARATION OF OPTICAL ISOMERS. |
| DE4326465A1 (en) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Amino acid derivatives, pharmaceutical compositions containing these compounds and process for their preparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4888485A (en) * | 1984-10-19 | 1986-04-24 | Nihon Medi-Physics Co., Ltd. | Estriol-3-sulfate protein conjugates and antibodies thereto |
| AU7462887A (en) * | 1986-06-20 | 1987-12-24 | Schering Aktiengesellschaft | Complex compounds |
| AU6340186A (en) * | 1985-11-12 | 1988-04-14 | Omnichem | Conjugates of vinblastine and protein |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310675A (en) * | 1976-09-29 | 1982-01-12 | Becton Dickinson & Company | Monoradioiodinated imidazole derivatives |
-
1981
- 1981-07-01 FR FR8112934A patent/FR2508905B1/fr not_active Expired
-
1982
- 1982-06-22 US US06/390,938 patent/US4529713A/en not_active Expired - Fee Related
- 1982-06-28 EP EP82401188A patent/EP0069018B1/en not_active Expired
- 1982-06-28 EP EP84201524A patent/EP0154045A3/en not_active Withdrawn
- 1982-06-28 AT AT82401188T patent/ATE18214T1/en not_active IP Right Cessation
- 1982-06-28 DE DE8282401188T patent/DE3269359D1/en not_active Expired
- 1982-06-30 DK DK294082A patent/DK165368C/en not_active IP Right Cessation
- 1982-06-30 IE IE1591/82A patent/IE54489B1/en not_active IP Right Cessation
- 1982-06-30 CA CA000406423A patent/CA1207775A/en not_active Expired
- 1982-06-30 AU AU85488/82A patent/AU558848B2/en not_active Ceased
- 1982-07-01 NZ NZ201130A patent/NZ201130A/en unknown
-
1984
- 1984-01-18 AR AR84295461A patent/AR244205A1/en active
-
1986
- 1986-10-06 AU AU63535/86A patent/AU579751B2/en not_active Ceased
- 1986-10-06 AU AU63536/86A patent/AU599603B2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4888485A (en) * | 1984-10-19 | 1986-04-24 | Nihon Medi-Physics Co., Ltd. | Estriol-3-sulfate protein conjugates and antibodies thereto |
| AU6340186A (en) * | 1985-11-12 | 1988-04-14 | Omnichem | Conjugates of vinblastine and protein |
| AU7462887A (en) * | 1986-06-20 | 1987-12-24 | Schering Aktiengesellschaft | Complex compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0154045A2 (en) | 1985-09-11 |
| AU558848B2 (en) | 1987-02-12 |
| DK165368B (en) | 1992-11-16 |
| AU6353686A (en) | 1987-01-08 |
| DK294082A (en) | 1983-01-02 |
| IE821591L (en) | 1983-01-01 |
| US4529713A (en) | 1985-07-16 |
| FR2508905B1 (en) | 1984-01-27 |
| FR2508905A1 (en) | 1983-01-07 |
| EP0069018A3 (en) | 1983-02-09 |
| EP0154045A3 (en) | 1986-02-05 |
| EP0069018A2 (en) | 1983-01-05 |
| ATE18214T1 (en) | 1986-03-15 |
| NZ201130A (en) | 1985-08-30 |
| CA1207775A (en) | 1986-07-15 |
| AR244205A1 (en) | 1993-10-29 |
| DK165368C (en) | 1993-04-05 |
| DE3269359D1 (en) | 1986-04-03 |
| EP0069018B1 (en) | 1986-02-26 |
| AU8548882A (en) | 1983-01-06 |
| AU6353586A (en) | 1987-01-08 |
| AU579751B2 (en) | 1988-12-08 |
| IE54489B1 (en) | 1989-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gurd | [34a] Carboxymethylation | |
| DE3751537T2 (en) | Polypeptide and protein derivatives and process for their preparation. | |
| Mullen et al. | A new fluoridolyzable anchoring linkage for orthogonal solid-phase peptide synthesis: design, preparation, and application of the N-(3 or 4)-[[4-(hydroxymethyl) phenoxy]-tert-butylphenylsilyl] phenyl pentanedioic acid monoamide (Pbs) handle | |
| Horton et al. | Dimethyl (2-hydroxy-5-nitrobenzyl) sulfonium Salts: Water-Soluble Environmentally Sensitive Protein Reagents | |
| Tager et al. | Studies on the Conversion of Proinsulin to Insulin: II. Evidence for a chymotrypsin-like cleavage in the connecting peptide region of insulin precursors in the rat | |
| May et al. | N epsilonB29-(+)-biotinylinsulin and its complexes with avidin. Synthesis and biological activity. | |
| KR0126238B1 (en) | Diethylenetriamine pentaacetic acid derivative | |
| EP0279365B1 (en) | Biotinylating agents | |
| Levy | Preparation of photo-affinity probes for the insulin receptor site in adipose and liver cell membranes | |
| Wadzinski et al. | Localization of the forskolin photolabelling site within the monosaccharide transporter of human erythrocytes | |
| CA1071101A (en) | Radioimmunoassay method for the determination of cardiotonic glycosides | |
| AU599603B2 (en) | Process for preparation of antigens using radio active stilbene derivatives labelled with iodine and the antigens obtained | |
| Crocker et al. | Heterobifunctional cross-linking agents incorporating perfluorinated aryl azides | |
| Mallory et al. | The incorporation of tritium-labelled amino acids into insulins in rat pancreas in vitro | |
| JPH09508389A (en) | Phenylboronic acid complex | |
| JPH06107610A (en) | Protection of allyl side chain in synthesis of peptide | |
| Tserng et al. | Bile acid sulfates: II. Synthesis of 3-monosulfates of bile acids and their conjugates | |
| Levy | The selective chloromercuration of insulin | |
| Canova-Davis et al. | Semisynthesis of insulin: specific activation of the arginine carboxyl group of the B chain of desoctapeptide-(B23-30)-insulin (bovine) | |
| JPS6311626B2 (en) | ||
| DAY et al. | SYNTHESIS OF Nα‐FORMYL‐MET‐LEU‐PHE‐OH: AN INDUCER OF CHEMOTAXIS IN PERITONEAL POLYMORPHONUCLEAR NEUTROPHILS | |
| JPS6121240B2 (en) | ||
| Ozawa | Reaction of insulin with ethyl glycinate and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide | |
| Imai et al. | Photoaffinity heterobifunctional crosslinking reagents based on N-(azidobenzoyl) tyrosines | |
| Lay et al. | Terminal amino acids of human and bovine gamma globulin |